At RSNA 2025, Konstanze Diefenbach, Head of Radiology R&D at Bayer, discusses how the theme “Imaging the Individual” of the event aligns with the company’s focus on enabling clear, early diagnoses and supporting better treatment decisions for patients.
A key focus at this year’s meeting is the investigational low-dose MRI contrast agent gadoquatrane, with Bayer presenting new data in pediatric patients. Building on previously released adult results from the QUANTI program, the company now showcases evidence collected from children ranging from birth through young adulthood. With more than 1.5 million contrast-enhanced pediatric MRI exams performed annually – and demand continuing to rise – expanding clinical data in this area is increasingly important for routine practice and future imaging standards.
Beyond contrast media development, Diefenbach underscores the value of collaboration across the radiology ecosystem. Close interaction with academia, biotech, and industry partners enables the identification of synergies that help drive the next wave of imaging innovation and growth. These collaborations support advances across multiple modalities, including CT, MRI, and emerging fields within medical imaging.
Diefenbach also highlights the need for solutions that help radiologists achieve the best possible image for each patient. Whether through optimized contrast media, injector technologies, or greater connectivity to support workflow, the overarching goal is to make imaging more efficient and clinically aligned. As radiology continues to guide diagnosis, treatment planning, and therapeutic decisions, its central role remains vital in shaping the next generation of patient-centered care.
